This research project examines the function of carbohydrate chains that are O-linked to leukocyte cell- surface glycoproteins. By acting as the natural ligands of the selectin family of adhesion molecules, these glycoproteins control the rates of leukocyte adhesion in the human vasculature during normal immune response, inflammatory diseases and certain types of cardiovascular disorders. It is widely believed that controlling the rate of leukocyte adhesion in vascular disorders can lead to new therapies to combat these ailments. Thus, in the current proposal, we evaluate two mechanisms for controlling selectin-ligand binding.
In Aim 1, we develop and test the ability of unique molecules based on an unusual disaccharide carbohydrate structure (GalNAc(31,3GalNAca-O-Methyl) to competitively inhibit selectin binding interactions with its ligand. Our preliminary data suggests that this disaccharide alone can bind P- selectin. We also demonstrate that appropriate modification of this unit can dramatically enhance the binding affinity of the resulting carbohydrate for selectins, when compared with the prototypic selectin ligand sialyl Lewis-X.
In Aim 2, we test an approach where small-molecule metabolic inhibitors are designed based on the structure of monosaccharides that compose natural selectin ligands. These modified monosaccharidesare fed to cells in order to interfere with the biosynthesis of specific carbohydrate epitopes on the glycoprotein ligands of selectins. More specifically, these molecules are directed to alter either the core or terminal residues of glycans expressed by an important leukocyte selectin-ligand called PSGL-1 (P-selectin glycoprotein ligand- 1). We evaluate the ability and mechanism by which these chemical inhibitors permeate cells, engage and modify glycan biosynthetic pathways and inhibit cell adhesion.
In Aim 3, to complement the experimental work above, a Systems Biology based mathematical model is developed to simulate biochemical networks that regulate O-glycan biosynthesis in leukocytes. Many of the assumptions in this mathematical model are experimentally validated. Diverse experimental methods are applied to accomplish the above three aims. These include cell adhesion studies under controlled flow, in vivo experiments in a mouse model of acute inflammation, western blot analysis, molecular biology based approaches, flow cytometry, surface plasmon resonance and liquid chromatography. In the long run, we anticipate that small-molecule selectin-antagonists will be identified from this work that may aid future drug design. Mathematical models developed will enhance the application of metabolic engineering principles in the area of biological chemistry. Such analysis can also provide the rationale for the chemical synthesis of new inhibitors and for interpretation of experimental observations.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL063014-09
Application #
7746418
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Sarkar, Rita
Project Start
2001-04-01
Project End
2011-05-31
Budget Start
2009-12-01
Budget End
2011-05-31
Support Year
9
Fiscal Year
2010
Total Cost
$222,062
Indirect Cost
Name
State University of New York at Buffalo
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Stolfa, Gino; Mondal, Nandini; Zhu, Yuqi et al. (2016) Using CRISPR-Cas9 to quantify the contributions of O-glycans, N-glycans and Glycosphingolipids to human leukocyte-endothelium adhesion. Sci Rep 6:30392
Gupta, Rohitesh; Matta, Khushi L; Neelamegham, Sriram (2016) A systematic analysis of acceptor specificity and reaction kinetics of five human ?(2,3)sialyltransferases: Product inhibition studies illustrate reaction mechanism for ST3Gal-I. Biochem Biophys Res Commun 469:606-12
Mondal, Nandini; Stolfa, Gino; Antonopoulos, Aristotelis et al. (2016) Glycosphingolipids on Human Myeloid Cells Stabilize E-Selectin-Dependent Rolling in the Multistep Leukocyte Adhesion Cascade. Arterioscler Thromb Vasc Biol 36:718-27
Lo, Chi Y; Weil, Brian R; Palka, Beth A et al. (2016) Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): Pilot validation in porcine ischemia-reperfusion model. Biomaterials 74:19-30
Xue, Jun; Laine, Roger A; Matta, Khushi L (2015) Enhancing MS(n) mass spectrometry strategy for carbohydrate analysis: A b2 ion spectral library. J Proteomics 112:224-49
Liu, Gang; Neelamegham, Sriram (2015) Integration of systems glycobiology with bioinformatics toolboxes, glycoinformatics resources, and glycoproteomics data. Wiley Interdiscip Rev Syst Biol Med 7:163-81
Mondal, Nandini; Buffone Jr, Alexander; Stolfa, Gino et al. (2015) ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes. Blood 125:687-96
Liu, Gang; Neelamegham, Sriram (2014) A computational framework for the automated construction of glycosylation reaction networks. PLoS One 9:e100939
Patil, Shilpa A; Bshara, Wiam; Morrison, Carl et al. (2014) Overexpression of ?2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. Glycoconj J 31:509-21
Lo, Chi Y; Antonopoulos, Aristotelis; Dell, Anne et al. (2013) The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling. Biomaterials 34:8213-22

Showing the most recent 10 out of 42 publications